1
|
Jain P, Romaguera J, Nomie K, Zhang S, Wang L, Oriabure O, Wagner-Bartak N, Zhang L, Hagemeister F, Samaniego F, Westin J, Ju Lee H, Nastoupil L, Iyer S, Parmar S, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Wang M. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) - PHASE II TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Jain
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - K. Nomie
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Zhang
- Genomic Medicine; UTMDACC; Houston United States
| | - L. Wang
- Genomic Medicine; UTMDACC; Houston United States
| | - O. Oriabure
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - L. Zhang
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - H. Ju Lee
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Iyer
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - C. Ok
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - W. Chen
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - D. Santos
- Surgical Oncology; UTMDACC; Houston United States
| | - M. Badillo
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - M. Wang
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| |
Collapse
|
2
|
Strati P, Ahmed M, Fowler N, Hagemeister F, Fayad L, Rodriguez M, Samaniego F, Wang M, Westin J, Romaguera J, Noorani M, Phansalkar K, Cheah C, Feng L, Davis R, Nastoupil L, Neelapu S. PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.22_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Strati
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Ahmed
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Wang
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J.R. Westin
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Noorani
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Phansalkar
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - C. Cheah
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Feng
- Biostatistics; MD Anderson Cancer Center; Houston United States
| | - R.E. Davis
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S.S. Neelapu
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
3
|
Westin J, Nastoupil L, Hagemeister F, Fayad L, Young K, McDonnell T, Chuang H, Ahmed S, Nair R, Steiner R, Lee H, Rodriguez M, Parmar S, Green M, Neelapu S, Davis R. SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.48_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Young
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - T. McDonnell
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Chuang
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Nair
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Steiner
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Green
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Davis
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
4
|
Strati P, Adkins S, Nastoupil L, Westin J, Hagemeister F, Fowler N, Lee H, Fayad L, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich V, Ariza Heredia E, Neelapu S. CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI-CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.120_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Strati
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Adkins
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - H.J. Lee
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - A. Varma
- Stem Cell Transplant; MD Anderson Cancer Center; Houston United States
| | - S. Arafat
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Johncy
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - P. Kebriaei
- Stem Cell Transplant; MD Anderson Cancer Center; Houston United States
| | - V.E. Mulanovich
- Infectious Disease; MD Anderson Cancer Center; Houston United States
| | - E. Ariza Heredia
- Infectious Disease; MD Anderson Cancer Center; Houston United States
| | - S.S. Neelapu
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
5
|
Westin J, Nastoupil L, Fayad L, Hagemeister F, Young K, McDonnell T, Neelapu S, Davis R, Green M, Ahmed S, Nair R, Steiner R, Lee H, Rodriguez M, Parmar S, Chuang H. VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.79_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Young
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - T. McDonnell
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R.E. Davis
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Green
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Nair
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Steiner
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Chuang
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
6
|
Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, Nogueras Gonzales G, Zhang L, Wagner-Bartak N, Hagemeister F, Samaniego F, Westin J, Lee H, Nastoupil L, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Romaguera J. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL). Hematol Oncol 2019. [DOI: 10.1002/hon.12_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - P. Jain
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Zhang
- Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - K. Nomie
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Wang
- Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - O. Oriabure
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - G. Nogueras Gonzales
- Biostatistics; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Zhang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - N. Wagner-Bartak
- Nuclear Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - H.J. Lee
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - C. Ok
- Hemato-pahtology; University of Texas MD Anderson Cancer Center; Houston United States
| | - R. Kanagal-Shamanna
- Hemato-pahtology; University of Texas MD Anderson Cancer Center; Houston United States
| | - W. Chen
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Thirumurthi
- Gastroenterology; University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Santos
- Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston United States
| | - M. Badillo
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| |
Collapse
|
7
|
Milgrom S, Pinnix C, Sheu T, Qiao W, Fowler N, Westin J, Nastoupil L, Hagemeister F, Oki Y, Fanale M, Fayad L, Lee H, Hosing C, Nieto Y, Shpall E, Dabaja B. Radiation As an Effective Salvage Therapy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Milgrom S, Lee J, Wang Q, Court L, Ng A, Pinnix C, Dabaja B, Akhtari M, Aristophanous M, Mawlawi O, Andraos T, Lee H, Hagemeister F, Oki Y, Fanale M, Sulman E, Smith G. Importance of PET-CT Radiomics Features in Outcomes Prognostication for Mediastinal Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Sheu T, Milgrom S, Dabaja B, Andraos T, Chi L, Nastoupil L, Fowler N, Westin J, Neelapu S, Lee H, Hagemeister F, Oki Y, Fanale M, Fayad L, Turturro F, Samaniego F, Pinnix C. Consolidative Radiation Dose De-escalation in Primary CNS Lymphoma for Patients with an Incomplete Response to Methotrexate Based Chemotherapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Pinnix C, Andraos T, Qiao W, Milgrom S, Cella L, Pacelli R, Nastoupil L, Hagemeister F, Lee H, Fanale M, Dabaja B. Potential to Reduce Toxicity: Clinical and Dosimetric Predictors of Hypothyroidism After Radiation Therapy With IMRT for Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Wang M, Lee H, Thirumurthi S, Chuang H, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Oriabure O, Feng L, Zhou S, Huang S, Li S, Zhang L, Badillo M, Wu L, Ahmed M, Yan F, Nomie K, Lam L, Addison A, Romaguera J. IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_132] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M.L. Wang
- Department of Lymphoma/Myeloma, Department of Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson; Houston USA
| | - H. Lee
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - S. Thirumurthi
- Department of Gastroenterology; University of Texas MD Anderson; Houston USA
| | - H. Chuang
- Department of Nuclear Medicine; University of Texas MD Anderson; Houston USA
| | - F. Hagemeister
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - J. Westin
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Fayad
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Samaniego
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Turturro
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - W. Chen
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - O. Oriabure
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Feng
- Department of Biostatistics; University of Texas MD Anderson; Houston USA
| | - S. Zhou
- Department of Biostatistics; University of Texas MD Anderson; Houston USA
| | - S. Huang
- Department of Interventional Radiology; University of Texas MD Anderson; Houston USA
| | - S. Li
- Department of Hematopathology; University of Texas MD Anderson; Houston USA
| | - L. Zhang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - M. Badillo
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Wu
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - M. Ahmed
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Yan
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - K. Nomie
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Lam
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - A. Addison
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - J. Romaguera
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| |
Collapse
|
12
|
Westin J, Fayad L, Oki Y, Nastoupil L, Hagemeister F, Turturro F, Lee H, Rodriguez A, Young K, McDonnell T, Ford R, Neelapu S, Davis R. RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_51] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - Y. Oki
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - F. Hagemeister
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - F. Turturro
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - H.J. Lee
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - A. Rodriguez
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - K.H. Young
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - T. McDonnell
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - R. Ford
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - S. Neelapu
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - R.E. Davis
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| |
Collapse
|
13
|
Fowler N, Samaniego F, Turturro F, Neelapu S, Forbes S, Westin J, Fayad L, Fanale M, Feng L, Arafat J, Neal E, Hagemeister F, Nastoupil L. THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N.H. Fowler
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Samaniego
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Turturro
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - S. Neelapu
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - S. Forbes
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - J. Westin
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - M. Fanale
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Feng
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - J. Arafat
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - E. Neal
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Hagemeister
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| |
Collapse
|
14
|
Pinnix C, Westin J, Ahmed M, Reed V, Romaguerra J, Oki Y, Rodriguez M, Fayad L, Hagemeister F, Kwak L, Medeiros L, Francesco T, Davis R, Chuang H, Davis R, Dabaja B. The Role of Radiation Therapy in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Rituximab containing Regimens. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Dabaja B, Liang F, Shihadeh F, Etzel C, Medeiros L, Fayad L, Oki Y, Hagemeister F, Rodriguez A. Mid-therapy Positron Emission Tomography Scans Significantly Predict Outcome in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Treated With Chemotherapy Alone But Not When Consolidation Radiation is Added. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
16
|
Dabaja BS, Phan J, Medeiros L, Chuang H, Fayad L, Hagemeister F, Shihadeh FD, Allen P, Rodriguez MA. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large B-cell Lymphoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Lacerte L, Fowler NH. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8030] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Fowler NH, McLaughlin P, Kwak L, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8548] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8548 Background: Despite advances in therapy and a better understanding of the natural history of indolent non-Hodgkins lymphomas (NHL), the optimal treatment for newly diagnosed patients (pts) has not been determined. While several combination chemotherapy regimens have response rates approaching 90%, toxicity is common with genotoxic drugs and secondary malignancies is a concern. Lenalidomide has been shown to have single agent activity in indolent NHL, and is approved for the treatment of multiple myeloma and myelodysplastic syndrome. Rituximab is effective as a single agent and in combination with chemotherapy for indolent NHL. The aim of this phase II, single arm study is to evaluate the efficacy and safety of lenalidomide and rituximab in pts with untreated, stage III, or IV indolent NHL. Methods: Pts with indolent NHL who were previously untreated, with measurable disease (>1.5 cm), were eligible for enrollment. Pts received 20mg of lenalidomide orally once daily on days 1–21 and rituximab 375mg/m2 intravenously on day 1 of each 28 day cycle. Pts could receive up to 6 cycles of therapy. Response was assessed after 3 cycles and at the end of therapy using the International Working Group Response Criteria. Results: At time of this report 17 pts have been enrolled and 14 are eligible for safety evaluation. The median age was 55 (33–77) years and 53% were male. Therapy was well tolerated with the following grade 3 adverse events (AE) reported; myalgia (1 pt), rash (1 pt), peripheral neuropathy (1pt). There were no grade 4 AEs. There have been no reported grade 3/4 hematologic AEs. There has been no tumor flare observed. In the 5 pts eligible for response assessment, 4 pts (80%) attained a complete response (CR), 1 patient (20%) had stable disease (SD). After 3 cycles, one patient had unconfirmed stable disease who also was previously treated with combination chemotherapy for Hodgkin's lymphoma. Updates for response will be presented. Conclusions: The combination of lenalidomide and rituximab has activity and is well tolerated with minimal toxicity in patients with newly diagnosed indolent lymphoma. [Table: see text]
Collapse
Affiliation(s)
| | | | - L. Kwak
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | - M. Fanale
- UT M. D. Anderson Cancer Center, Houston, TX
| | - L. Fayad
- UT M. D. Anderson Cancer Center, Houston, TX
| | - B. Pro
- UT M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
19
|
Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Wayne Saville M, Kwak L. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009; 20:709-14. [DOI: 10.1093/annonc/mdn692] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
20
|
Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8030] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8030 Background: MCL remains a therapeutic challenge. R targets CD20 antigen on MCL cells while Len may target the microenvironment of MCL cells and enhance the ADCC activity of R. To test this hypothesis, we initiated a single-center; open label, phase I/II study. We now report the completed phase I. Methods: Eligible patients (pts) had 1–4 lines of prior therapy including prior thalidomide or R, regardless of resistance. Each cycle of treatment consisted of Len given orally daily on days 1–21 of a 28-day cycle and R 375 mg/m2 by IV infusion weekly for 4 weeks. A standard 3+3 dose escalation was used to determine MTD with Len doses at 10 mg, 15 mg, 20 mg, and 25 mg. DLT was defined as grade (G) 3 or 4 non-hematologic or G4 hematologic toxicity during the first cycle. Results: The phase I portion completed enrollment with 15 pts (4 at 10 mg, 3 at 15 mg, 6 at 20 mg and 2 at 25 mg). Thirteen pts were evaluable. Median age was 73 (62–84); median prior lines of therapy were 3 (1–4); median cycles received to date were 2 (1–7). Two DLT's occurred at 25 mg. One pt had G3 hypercalcemia. The other had G4 neutropenic fever and died of sepsis (G5) during the first cycle. Three additional pts were therefore enrolled at 20 mg. Common non-hematologic toxic events included pruritis (21 G1–2), hypercalcemia (9 G1–2, 1 G3), fatigue (9 G1–2), constipation (8 G1), diarrhea (6 G1–2), fever (6 G1–2), myalgias (4 G1–2, 1 G3) and elevated LDH (4 G1–2, 1 G3). Hematologic events included neutropenia (20 G1–2, 4 G3), thrombocytopenia (6 G1–2, 2 G3) and anemia (6 G1). There were no responses at 10 mg or 15 mg. At 20 mg after 2 cycles, 5 out of 6 pts achieved responses including 1 CR, 1 PR, 3 minor responses (MRs) and only 1 pt progressed. The 1 pt with PR went on to achieve a CR after 6 cycles. The 3 pts with MRs had tumor reductions by 43%, 40% and 38% respectively. These 3 patients with MRs continue to receive Len and might later achieve PR or CR. Conclusions: The MTD for Len with R in relapsed/refractory MCL was 20 mg, orally daily on days 1–21 of a 28-day cycle. Responses observed at 20 mg are promising with a favorable toxicity profile and are being evaluated further in an ongoing phase II study. [Table: see text]
Collapse
Affiliation(s)
- M. Wang
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - L. Fayad
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - F. Hagemeister
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - S. Neelapu
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - N. Bell
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - C. Byrne
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - R. Knight
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - J. Zeldis
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - L. Kwak
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| | - J. Romaguera
- UT MD Anderson Cancer Center, Houston, TX; Celgene Corporation, Summit, NJ
| |
Collapse
|
21
|
Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, Cabanillas F. Predictive value for survival of a risk model of two serological markers, beta-2-microglobulin (B2M) and lactic dehydrogenase (LDH), in diffuse large cell lymphoma (DLCL). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10599 Background: The International Prognostic Index (IPI), the standard tumor risk model in patients (pts) with diffuse large cell lymphoma (DLCL), has 5 factors (age, LDH, performance status, extra nodal sites, and stage). We previously proposed a simpler two-factor model, based on LDH and B2M (JCO10;1989). B2M is a component of HLA class I antigens, expressed in lymphocytes, and a known prognostic indicator in some lymphoid malignancies. The benefits of this model are: objective measures; lab method widely available; simplicity; biologic marker. Methods: We applied the model to a large cohort of DLCL patients with prospective baseline B2M, and treated with doxorubicin-based (chemo) regimens, with and without rituximab. 718 pts with DLCL were sequentially treated at MDACC by IRB approved chemo protocols from 1988–2000. In 2001, rituximab plus chemo (RCHOP) became standard. 311 DLCL pts were sequentially treated with RCHOP from 2001–2005. Cox regression analyses for univariate and multivariate models of IPI factors and B2M were done. Kaplan-Meier survival projections were in three risk categories: low (normal [nl] LDH and B2M); intermediate (either LDH or B2M > nl); or high (LDH and B2M > nl). Results: In both treatment groups, IPI factors and B2M were significant as univariate factors. In the RCHOP group, however, the IPI multivariate model showed age, stage, and extra-nodal sites were not significant risk factors, while B2M and LDH remained highly significant (p<0.01). The 5 year survival projections by risk category were: (*) combines intermediate low and intermediate-high categories Conclusions: This simple two-factor model predicts risk for patients with DLCL, treated with or without rituximab, comparably to the IPI. B2M should be considered an important prognostic indicator in DLCL, particularly in rituximab treated patients. Exploratory analyses to revise the IPI model are indicated. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. A. Rodriguez
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - S. Temple
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - L. Fayad
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - F. Hagemeister
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - P. McLaughlin
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - J. Romaguera
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| | - F. Cabanillas
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Instituto Auxilio Mutuo, San Juan, PR
| |
Collapse
|
22
|
Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaiego F, McLaughlin P, Wang M, Kwak L, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M. D. Anderson experience in 40 patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8058 Background: R-HCVAD (rituximab-cyclphosphamide, vincristine, dexamethasone, doxorubicin) alternating with R-MTX-ARAC (rituximab, methotrexate-cytarabine) is a chemoimmunotherapy regimen with activity in ALL, mantle cell, and Burkitt’s lymphomas (BL). Histological differentiation between BL, atypical BL, and DLBCL with high-grade features can be difficult. We thus have treated patients with DLBCL with high-grade histological features and/or poor-risk IPI with R-HCVAD. Methods: Forty consecutive patients with information collected prospectively in the NCCN database, treated between 7/2002 and 10/05 at M.D Anderson Cancer Center, and who received at least one cycle are included in this cohort analysis. Characteristics: 18 (45%) male; 18 (45%) HI and High IPI; 25 (62.5%) ↑LDH; 26 (65%) with Stage III/IV; 2 (5%) with PS>1; 8 (20%) with >60 years; 25 (62%) a Ki-67 >90%. Four patients received less than 4 cycles of treatment. Results: ORR was of 100%, with 95% CR/CRu. With a median follow-up of 26 months, 6 patients failed: 1 died in CR of pulmonary embolism while on treatment; 1 patient who achieved CR, had PD before the end of treatment; 1 achieved a PR and was transplanted (is alive in remission); 1 achieved a PR and progressed died of disease; and 2 relapsed (one is in remission after an ASCT). Four patients have died: 3 of disease, 1 of pulmonary embolism. The 3-year OS is 88% (95% CI 77%-99%); 3-year FFS is 71% (95% CI 47%-95%). The 3-year FFS for patients with L/LI risk (3-failures of 22 pts) was 78% (95% CI 52%-100%); and for patients with HI/H IPI (3 failures of 18 pts) 65% (95% CI 27%-100%). Conclusions: R-HCVAD/R-MTC-ARAC is a very active regimen for DLBCL of high grade. Toxicity was mostly hematological. We are currently doing a prospective randomized phase II study comparing this regimen to standard R-CHOP in patients with poor-risk IPI scores. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Fayad
- MD Anderson Cancer Ctr, Houston, TX
| | | | - B. Pro
- MD Anderson Cancer Ctr, Houston, TX
| | | | | | | | | | - M. Wang
- MD Anderson Cancer Ctr, Houston, TX
| | - L. Kwak
- MD Anderson Cancer Ctr, Houston, TX
| | | | | |
Collapse
|
23
|
Fayad L, Romaguera J, Hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Fayad
- MD Anderson Cancer Ctr, Houston, TX
| | | | - S. Hart
- MD Anderson Cancer Ctr, Houston, TX
| | | | - B. Pro
- MD Anderson Cancer Ctr, Houston, TX
| | | | | | - N. Dang
- MD Anderson Cancer Ctr, Houston, TX
| | | | | | - F. Gil
- MD Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
24
|
Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:1015-23. [PMID: 15048145 DOI: 10.1038/sj.bmt.1704483] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34% (95% CI 27-42) and 29% (95% CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.
Collapse
Affiliation(s)
- U Popat
- Department of Blood and Marrow Transplant, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Goy
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - A. Younes
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - P. McLaughlin
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - B. Pro
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - J. Romaguera
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - F. Hagemeister
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - L. Fayad
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - E. G. Trehu
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - D. Schenkein
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - M. A. Rodriguez
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| |
Collapse
|
26
|
Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001; 50:971-7. [PMID: 11429225 DOI: 10.1016/s0360-3016(01)01525-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE We performed a retrospective study to determine the long-term outcome, patterns of failure, and prognostic factors for patients with pathologic Stage I or II Hodgkin's disease (HD) who were treated with mantle irradiation alone. METHODS AND MATERIALS The medical records of 145 patients with pathologic Stage I or II supradiaphragmatic Hodgkin's disease treated with mantle irradiation alone between June 1967 and June 1991 were reviewed. Patterns of failure, overall survival (OS) rate, and progression-free survival (PFS) rate were determined. Univariate and multivariate analyses were performed to identify adverse prognostic factors for OS and PFS. The number of adverse prognostic factors per patient was counted, and a prognostic score was assigned to each patient. The log-rank test was used to compare the OS or PFS rates among patients with prognostic scores 0, 1, and 2. RESULTS The median patient age was 27 years (range 10-66), with almost even male to female distribution. Every patient had splenectomy and negative laparotomy (LAP). Fifty-one patients had Stage I disease (IA-49, IB-2) and 94 Stage II (IIA-89, IIB-5). The histologic subtypes were nodular sclerosing in 110, mixed cellularity in 28, lymphocyte predominance in 5, lymphocyte depleted in 1, and unclassified in 1. Twelve patients with Stage II disease had >/= 3 sites of nodal involvement. Fifty-four patients had a prognostic score of 0, 70 of 1, and 21 of 2. The median follow-up time for the 109 surviving patients was 146 months (range 25-381). The 10- and 20-year actuarial OS rates for the whole group were 87.6% and 65.3%, respectively. The corresponding actuarial PFS rates were 75.3% and 74.2%, respectively. Thirty-six patients (9 Stage I, 27 Stage II) had relapses in a total of 41 sites. Failures by histology were 29 patients with nodular sclerosing, 6 with mixed cellularity, and 1 with lymphocyte predominance. Failures by sites were: trans-diaphragmatic, 22 (para-aortic nodes, 15; as the only site of progression in 12; visceral, 7; as the only site of progression in 5); within radiation field, 8; marginal miss, 8 (as the only site of failure in 2); and unknown, 3. The majority of the failures occurred within 5 years of diagnosis. Long-term side effects of radiation included cardiac complications in 30 patients, with 10- and 20-year actuarial cardiac complication rates of 12.6% and 35.1%, respectively; secondary solid tumors in 14, with 10- and 20-year actuarial rates of 2.3% and 25.7%, respectively; leukemia in 4; non- Hodgkin's lymphoma in 4, with the 10- and 20-year actuarial rates for leukemia and non-Hodgkin's lymphoma of 4.0% and 13.9%; and hypothyroidism in 38. Four adverse prognostic factors were identified for PFS: age > or = 40 years, > or = 3 sites of involvement, male sex, and constitutional symptoms. The prognostic score correlated with patients' outcome as indicated by PFS and OS rates. Patients with a prognostic score of 0 did significantly better than those with a score of 1 or 2. CONCLUSION In this select group of patients with pathologic Stage I and II Hodgkin's disease treated with mantle irradiation alone, the OS and PFS rates at 10 and 20 years were comparable to those reported in the literature. The major pattern of disease progression was relapse below the diaphragm, therefore close surveillance of the abdomen is warranted. The prognostic score used in our series may predict the patient's outcome, and might be worth testing in a prospective trial. In our series, patients with a prognostic score of 0 had excellent long-term survival, indicating adequate treatment with mantle irradiation alone. Late complications of the treatment pose a significant threat for the patient's survival with long-term follow-up.
Collapse
Affiliation(s)
- Z Liao
- Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 2000; 11:1551-6. [PMID: 11205462 DOI: 10.1023/a:1008330311886] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE Investigators disagree on whether follicular large cell lymphoma (FLCL) behaves like other follicular lymphomas, with no plateau in the survival curve, or as a more aggressive but potentially curable lymphoma. We reported in 1984 results for 62 FLCL patients treated at our institution; the current report updates those results. PATIENTS AND METHODS Sixty-two patients referred from 1973-1981, including fifteen (24%) patients with Ann Arbor stage I-II and forty-seven (76%) with stage III-IV FLCL. Seven patients received radiation (XRT) alone, forty patients XRT and chemotherapy, and fifteen patients received chemotherapy alone. RESULTS The median follow-up was 14.7 years. The median survival was 5.1 years, with 21% alive at 15 years. The failure-free survival (FFS) at 10 years was 31%. Univariate analysis revealed that age, Ann Arbor stage, and the International Index correlated with survival. Performance status, number of platelets, and LDH correlated with failure-free survival. CONCLUSIONS FLCL responds to doxorubicin-based regimens similarly to diffuse large cell lymphoma. Patients with FLCL have the potential for prolonged failure-free survival. Variables that predict the survival in aggressive lymphomas apply as well in this type of lymphoma.
Collapse
Affiliation(s)
- J Rodriguez
- University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 2000; 39:291-9. [PMID: 11342309 DOI: 10.3109/10428190009065828] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Vinorelbine (Navelbine is a semisynthetic vinca alkaloid devoid of serious neurotoxicity. When given weekly vinorelbine has documented activity against many tumors, including lymphomas. Since weekly schedules cannot be easily incorporated in combination regimens, we tested an infusional schedule of vinorelbine given every 21 days in adults with relapsed or refractory lymphoma. Patients with inadequate organ or bone marrow reserve, HIV or other serious infection, central nervous system disease, or prior stem cell or bone marrow transplantation were ineligible. In the phase I part, patients received a constant intravenous bolus of 8 mg/m(2), followed by intravenous continuous infusion over 24 hours daily for four days increasing from 10, 12, to 14 mg/m(2) /d in successive three-patient cohorts. Cycles were repeated every 21 days, and the daily continuous infusion dose was adjusted for toxicity. Dose-limiting mucositis and neutropenia were reached at the continuous dose of 14 mg/m(2) /d. Consequently, for the Phase II trial the starting continuous infusion dose was 12 mg/m(2) /d. After the first 19 patients were entered in the phase II study, the starting infusion dose was reduced to 10 mg/m(2) /d because of frequent grade (3/4) myelosuppression and mucositis. Forty-four patients were entered in the phase II study, of whom 41 are evaluable. Median age was 61 years, 23 were males, with clinically aggressive non-Hodgkin's lymphoma (NHL) in 22, indolent NHL in 18, and Hodgkin's Disease in one patient. The median number of prior regimens was 3 (range 1-11). The lymphoma was refractory to the initial regimen in nine patients, and to the regimen immediately before vinorelbine in 20 patients. Serum LDH was high in 2(1/4)1, and serum beta(2) -microglobulin > 3.0 mg / L in 16/31 patients. Responses were observed in four of 22 patients with aggressive NHL (18%, 95% confidence interval 5%-40%), and in six of 18 with indolent NHL (33%, 95% confidence interval 13%-59%). Median progression-free survival was 6 months for responders. During the Phase II trial 114 vinorelbine courses were administered. Neutrophil nadir was < 1000/microl in 65% and < 100/microl in 35% of courses, respectively. Platelet nadir was < 100,000/microl in 30% and < 20,000/microl in 8% of courses, respectively. Grade (3/4) mucositis was seen in 18% of courses, and neutropenic fever in 13%, and was complicated by death in one patient. We conclude that this dosage and schedule of vinorelbine has modest activity in patients with relapsed or refractory NHL. Myelosuppression is frequent but reversible, but there is no significant neurotoxicity. The role of vinorelbine in combination regimens for patients with relapsed lymphomas, particularly those of indolent histology, should be further investigated.
Collapse
Affiliation(s)
- A H Sarris
- Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26:615-20. [PMID: 11041566 DOI: 10.1038/sj.bmt.1702580] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Six patients with advanced Hodgkin's disease in which multiple conventional treatments (median prior chemotherapy regimens: seven), radiation therapy, and a prior autologous stem cell transplantation (SCT) had failed underwent allogeneic SCT following a fludarabine-based conditioning regimen. Median age was 29 years (22-30). Median time to progression after autologous SCT was 6 months (4-21). Disease status at transplant was refractory relapse (n = 3) and sensitive relapse (n = 3). Cell source was filgrastim-mobilized peripheral blood stem cells from an HLA-identical sibling (n = 4) or matched unrelated donor marrow (n = 2). Conditioning regimens were fludarabine-cyclophosphamide-antithymocyte globulin (n = 4), fludarabine-melphalan (n = 1) and fludarabine-cytarabine-idarubicin (n = 1). Myeloid recovery was prompt, with an absolute neutrophil count > or =500/microl on day 12 (11-15). Median platelet recovery to > or =20000/microl was on day 9 (0-60). Chimerism studies on day 30 indicated 100% donor-derived hematopoiesis in 4/5 evaluable patients (4/4 non-progressors). All responders (3/3) have ongoing 100% donor-derived chimerism. Acute graft-versus-host disease (GVHD) was diagnosed in 4/6 evaluable patients. Chronic GVHD was present in 2/4 evaluable patients. There were no regimen-related deaths. Overall day 100 transplant-related mortality was 2/6 (33%). Three patients have expired and three are alive and progression-free with a median follow-up of 9 months (6-26) post transplant. We conclude that allogeneic stem cell transplantation with fludarabine-based preparative regimens is feasible in these high-risk, heavily pretreated HD patients.
Collapse
Affiliation(s)
- P Anderlini
- Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000; 11 Suppl 1:137-40. [PMID: 10707796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
BACKGROUND We have observed that molecular response, as defined by a PCR-negative status during the first year of therapy, along with beta 2-microglobulin (beta 2M), was the most important variable associated with failure-free survival (FFS) in follicular lymphoma (FL). Herein, we present an update of the previously published MDACC series. PATIENTS AND METHODS A total of 116 patients (male:female ratio 64:52; median age: 52 years) with indolent FL and BCL-2 rearrangement (at MBR or mcr breakpoints) assessable in peripheral blood (pb) by PCR prior to treatment, and with two or more PCR determinations during the first year, were selected for the present study. RESULTS Of the 116 patients, 4 who presented with progression and 1 who died of unrelated causes during the first year were excluded from the landmark analysis. One hundred patients (86%) achieved clinical CR and 80 (69%) achieved a negative PCR status within first year. Median FFS was 6.4 years. Five-year FFS was 73% and 28% for molecular responders and nonresponders, respectively (P = 0.001). In spite of this strikingly higher FFS favoring molecular responders, no clearcut plateau was evident in this group. Molecular response assessed in pb (P = 0.001) and serum beta 2M (P < 0.001) were the most important factors to predict FFS in the multivariate analysis. In the subset of patients with normal beta 2M and molecular CR, there was a trend for a plateau in the FFS curve. No significant difference between the groups has been observed so far in terms of survival. CONCLUSIONS Molecular response assessed in pb using a PCR technique is, along with beta 2M, the most important factor to predict FFS in FL.
Collapse
Affiliation(s)
- A López-Guillermo
- Department of Lymphoma, University of Texas, M.D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000; 11:69-72. [PMID: 10690390 DOI: 10.1023/a:1008348010437] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Vincristine is an active agent in lymphomas, but is often neurotoxic, and the resulting dose reductions have been associated with lower remission and survival rates in Hodgkin's disease. Liposomal vincristine (Onco-TCS) has prolonged half-life, reaches higher concentration in tumors and lymph nodes than in nerves, and administered at full doses appears to be less neurotoxic, and more active then free vincristine in mice bearing L-1210 and P-388 leukemias. We therefore explored its activity in relapsed non-Hodgkin's lymphomas (NHL) and acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS Eligible patients had histologically proven relapse, age > or = 16 years, normal renal function, neutrophils > 500/microliter, platelets > 50,000/microliter, and no HIV infection, central nervous system disease, or serious neuropathy. Patients were treated with 2.0 mg/m2 of liposomal vincristine i.v. over 60 minutes q 14 days. Responders received up to 12 injections. RESULTS Of the 51 registered patients, 35 are currently evaluable for response. Median age was 62 years (range 19-86), and 21 were male. The median number of prior regimens was 3 (range 1-10) and had included vincristine in all patients, of whom 51% were refractory to their last regimen. Serum LDH was high in 46%, and beta 2-microglobulin > 3.0 mg/l in 63% of patients. Of the 155 administered injections, 138 (89%) were at the 2.0 mg/m2 level. The median injected dose was 3.8 mg (range 2.6-4.8 mg), and median number of injections was 4 (range 1-12). Responses were seen in 14 of 34 (41%) patients with NHL (95% confidence intervals (95% CI) 25%-59%). Response rates were 10% for indolent, 71% for transformed, and 47% for aggressive NHL, but the 95% confidence intervals overlapped. Median progression-free survival was 5.5 months for responders. Grade 3-4 motor or sensory neuropathy was seen in 11, and caused termination of therapy in five patients. All five had prior neuropathy, two had previously received paclitaxel, one platinum, and two paclitaxel and platinum. Fever was detected in three patients, but there were no toxic deaths. CONCLUSIONS Liposomal vincristine is active and well tolerated in this heavily pretreated population with relapsed NHL, but can be neurotoxic in a fraction of patients heavily exposed to prior neurotoxic agents. These data, if confirmed, would suggest a potential role for liposomal vincristine in the combination therapy of previously untreated patients with NHL.
Collapse
Affiliation(s)
- A H Sarris
- Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Zheng N, Monckton DG, Wilson G, Hagemeister F, Chakraborty R, Connor TH, Siciliano MJ, Meistrich ML. Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy. Environ Mol Mutagen 2000; 36:134-145. [PMID: 11013412 DOI: 10.1002/1098-2280(2000)36:2<134::aid-em8>3.0.co;2-d] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
To determine whether the measurement of repeat number mutations at a minisatellite locus could detect human germline mutations induced by chemotherapy, we performed a longitudinal study of the mutation frequencies in sperm from 10 patients treated for Hodgkin's disease. Polymerase chain reaction on small pools of DNA equivalent to 100 sperm and Southern blotting were used to screen at least 7900 sperm in each sample to quantify the mutation frequency at the minisatellite MS205 locus. Pretreatment and posttreatment semen samples were obtained at least 2 months after completion of therapy from 4 patients treated with a regimen (Novantrone, Oncovin, vinblastine and prednisone [NOVP]) that lacks alkylating agents and from three patients treated with regimens (Cytoxan, vinblastine, procarbazine and prednisone/Adriamycin, bleomycin, dacarbazine, lomustine, and prednisone [CVPP/ABDIC] or mechlorethamine, Oncovin, procarbazine and prednisone [MOPP]) containing alkylating agents. There were no effects of NOVP or CVPP/ABDIC on the mutation frequencies. In the 1 patient treated with MOPP, the treatment with the highest dose of gonadotoxic alkylating agents, there was a statistically significant increase in mutation frequency from 0.79% pretreatment to 1.14% posttreatment, indicating induction of mutations in stem spermatogonia. During-treatment semen samples obtained from 2 patients treated with ABVD, which does not contain gonadotoxic alkylating agents, and 1 with NOVP also did not show any increases above the baseline mutation frequencies, indicating no increase in the minisatellite mutation frequency in spermatocytes. Thus, measurement of repeat number changes at minisatellite MS205 appears to be able to detect induced germline mutations in human sperm. However, most chemotherapy regimens do not significantly increase this class of mutations.
Collapse
Affiliation(s)
- N Zheng
- Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
33
|
López-guillermo A, Cabanillas F, Mclaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee M. Ann Oncol 2000; 11:137-140. [DOI: 10.1023/a:1008369623425] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez M, Romaguera J, Younes A, Sarris A, Preti H, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol 2000. [DOI: 10.1093/annonc/11.suppl_1.s137] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35:317-24. [PMID: 10706456 DOI: 10.3109/10428199909145736] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We studied 36 patients with non-Hodgkin's lymphoma to evaluate the stem cell yield following recovery from intensive dose ifosfamide and etoposide given as mobilization chemotherapy. We also assessed the toxicity of the regimen and engraftment kinetics. All patients had intermediate grade lymphoma and had either failed to achieve a complete remission to induction chemotherapy or had relapsed. Patients received ifosfamide 10 g/m2 IV total dose given over 72 hours, etoposide 150 mg/m2 IV every 12 hours for 6 doses and G-CSF 10 microg/kg/d. Thirty-four patients went on to receive high-dose chemotherapy with BEAM or with CVP and BEAM. A median of 2 (1-10) apheresis was required to reach the target CD34+ count of >4 x 10(6)/kg. A median of 13.1 CD34+ cells/kg (4.1-148) was obtained. Toxicity was limited to mucositis in 3 patients, transient confusion and transient rise in liver function tests in 3 and 2 patients respectively. The median time to engraftment was 10 days (8-17) for all the patients undergoing high-dose chemotherapy. The regimen of intensive dose ifosfamide and etoposide along with G-CSF is well tolerated and in this group of patients has lead to successful stem cell harvests and sustained engraftment.
Collapse
Affiliation(s)
- M L Donato
- The University of Texas MD Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999; 10:527-32. [PMID: 10416001 DOI: 10.1093/oxfordjournals.annonc.a010369] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The combination of carmustine, etoposide, cytarabine and melphalan (BEAM) is an effective autologous transplantation preparative regimen for lymphoma and has little toxicity, but the feasibility and tolerance of BEAM as a preparative regimen for allogeneic transplantation has not been established. PATIENTS AND METHODS Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m2 i.v. day -6, etoposide 200 mg/m2 i.v. followed by cytarabine 200 mg/m2 i.v. twice daily days -5 to -2, melphalan 140 mg/m2 i.v. day -1, and marrow or blood stem cells from an HLA-identical donor on day 0. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease (GVHD). RESULTS Median time from transplantation was 20 mos (range 6-32 months). Median maximal regimen-related toxicity grade was 2, and four patients (13%) had a grade 3-4 regimen-related toxicity. Two patients had idiopathic interstitial pneumonitis. One patient had primary graft failure, and a second had autologous reconstitution documented at three months posttransplant. Grades 2-4 acute GVHD occurred in 31%, grades 3-4 in 16%, and chronic GVHD in 54%. Day-100 survival was 70%. Twenty-three patients achieved a complete response. The two-year relapse rate was 23%, survival was 48%, and disease-free survival (DFS) was 42%. CONCLUSIONS BEAM supports engraftment of allogeneic transplants and is a tolerable preparative regimen for allogeneic transplantation for lymphoma.
Collapse
Affiliation(s)
- D Przepiorka
- Department of Blood and Marrow Transplantation, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
López-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93:3081-7. [PMID: 10216105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023] Open
Abstract
The t(14;18) translocation, which involves the bcl-2 oncogene, occurs in follicular lymphomas (FL) at two common sites: the major breakpoint region (MBR) and the minor cluster region (mcr). The biological and clinical significance of these breakpoints is unknown. The bcl-2 breakpoint site was determined in 247 previously untreated patients (49% men; median age 52 years) with indolent FL (155 grade I, 83 grade II, and 8 grade III) to correlate it with pretreatment characteristics, response, and outcome. The bcl-2 breakpoint site was determined by a polymerase chain reaction method of peripheral blood (all cases), bone marrows (149 cases), and fresh lymph node biopsy specimens (68 cases). The breakpoint site occurred at MBR in 175 cases (71%) and at mcr in 27 (11%). In 45 cases (18%), no breakpoint was detected (germline). No significant relationship was found between the rearrangements and the expression of BLC-2 and BAX proteins. Patients' germline for MBR and mcr tended to present more frequently with stage IV disease and higher beta2-microglobulin (beta2M) levels, whereas mcr-rearranged patients presented more frequently with early stage and normal beta2M. The complete response rate of germline patients was significantly lower than that of MBR and mcr patients. An estimated 3-year failure-free survival (FFS) for mcr, MBR, and germline cases was 95%, 76%, and 57%, respectively (P <.001). The bcl-2 breakpoint site was independent of serum beta2M and lactate dehydrogenase in its correlation with FFS. In conclusion, the bcl-2 rearrangement site is an important prognostic factor in indolent FL, useful to identify patients who may require different treatment.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bone Marrow/pathology
- Chromosome Aberrations
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 18
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Gene Rearrangement
- Genes, bcl-2
- Germ-Line Mutation
- Humans
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/therapy
- Male
- Middle Aged
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Radiotherapy/methods
- Survival Analysis
- Translocation, Genetic
- Treatment Outcome
Collapse
Affiliation(s)
- A López-Guillermo
- Departments of Myeloma/Lymphoma, Pathology, Biomathematics, and Laboratory Medicine, the University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803-9. [PMID: 9850025 DOI: 10.1200/jco.1998.16.12.3803] [Citation(s) in RCA: 282] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE Diffuse and nodular forms of mantle-cell lymphoma (MCL) are consistently associated with poor prognosis. In an effort to improve the outcome, we adopted a treatment plan that consisted of four courses of fractionated cyclophosphamide (CY) 1,800 mg/m2 administered with doxorubicin (DOX), vincristine (VCR), and dexamethasone (Hyper-CVAD) that alternated with high-dose methotrexate (MTX) and cytarabine (Ara-C). After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation. PATIENTS AND METHODS Forty-five patients were enrolled; 25 patients were previously untreated, 43 patients had Ann Arbor stage IV disease, and 42 patients had marrow involvement. Forty-one patients had diffuse histology, two patients had nodular, and two patients had blastic variants. RESULTS Hyper-CVAD/MTX-Ara-C induced a response rate of 93.5% (complete response [CR], 38%; partial response [PR], 55.5%) after four cycles of pretransplantation induction chemotherapy. All patients who went on to undergo transplantation achieved CRs. For the 25 previously untreated patients, the overall survival (OS) and event-free survival (EFS) rates at 3 years were 92% (95% confidence interval [CI], 80 to 100) and 72% (95% CI, 45 to 98) compared with 25% (95% CI, 12 to 62; P = .005) and 17% (95% CI, 10 to 43; P = .007), respectively, for the previously treated patients. When compared with a historic control group who received a CY, DOX, VCR, and prednisone (CHOP)-like regimen, untreated patients in the study had a 3-year EFS rate of 72% versus 28% (P = .0001) and a better OS rate (92% v 56%; P = .05). Treatment-related death occurred in five patients: all were previously treated and two received allogeneic transplants. CONCLUSION The Hyper-CVAD/MTX-Ara-C program followed by stem-cell transplantation is a promising new therapy for previously untreated patients with MCL.
Collapse
Affiliation(s)
- I F Khouri
- Department of Hematology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol 1998; 103:678-83. [PMID: 9858216 DOI: 10.1046/j.1365-2141.1998.01048.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Based on the single-agent activity of both paclitaxel and cyclophosphamide in the treatment of non-Hodgkin's lymphoma (NHL), we conducted a phase II study to evaluate the efficacy of the combination of the two drugs in patients with refractory and relapsed aggressive NHL. All patients received 900 mg/m2 bolus of cyclophosphamide intravenously daily for 3 consecutive days with a concurrent infusion of 150 mg/m2 of paclitaxel over 72 h (50 mg/m2/d). 24 h after the completion of chemotherapy, patients received subcutaneous injections of 5 microg/kg of granulocyte-colony stimulating factor (G-CSF) daily until white cell count recovery. Treatment was repeated every 3 weeks. Patients who had at least a partial response (PR) after two courses continued to receive a maximum of four courses. Patients with responding disease were allowed to undergo high-dose chemotherapy followed by stem-cell/bone marrow transplantation if they were eligible. Of the 77 patients who were eligible for the study, 74 (96%) were evaluable for toxicity and treatment response. The overall response rate was 45% (95% CI 33-57%). Patients who received treatment after their disease relapsed from a complete response (CR) had an 81% response rate (38% CRs), whereas those with primary refractory disease had a 22% response rate. Toxicities of > grade 2 included alopecia (100%) and stomatitis (25%). Neutropenic fever of grade > 2 occurred after 18% of the courses, and platelet count of < or = 20 x 10(9)/l developed after 20% of the courses. Thus, the combination of paclitaxel plus high-dose cyclophosphamide is an effective new regimen in the treatment of refractory and relapsed NHL.
Collapse
Affiliation(s)
- A Younes
- Department of Lymphoma, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91:2955-60. [PMID: 9531606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Most patients with follicular lymphoma (FL) achieve a complete response (CR) after treatment, but eventually most of them, particularly those with stage IV, relapse due to minimal residual disease (MRD). The t(14;18) gives rise to a rearrangement of the bcl-2 oncogene that constitutes an excellent target for detection of MRD by polymerase chain reaction (PCR). One hundred ninety-four previously untreated patients with indolent FL and detectable bcl-2 rearrangement were studied. The PCR assay was used to detect bcl-2-rearranged cells in blood and marrow before and after treatment. Molecular response rate was 37%, 53%, 56%, and 66% at 3 to 5, 6 to 8, 9 to 14, and 15 to 18 months from the start of therapy, respectively. Although molecular response was higher among clinical CRs, one third of partial responders at 3 to 5 months also achieved a molecular response. Patients who achieved a molecular response during the first year of treatment had a significantly longer failure-free survival (FFS) than those who did not (4-year FFS: 76% v 38%, respectively; P < .001). Similar results were also observed in the subset of patients in clinical CR 1 year after treatment. By multivariate analysis, beta2-microglobulin (beta2-M; P < .01), and molecular response (P < .001) were the most important variables associated with outcome. When we combined beta2-M and molecular response, three prognostic groups emerged: (1) low beta2-M and molecular responders, (2) low beta2-M and nonresponders or high beta2-M and responders, and (3) high beta2-M and nonresponders. The 4-year FFS of these 3 groups were 86%, 65%, and 23%, respectively. Finally, patients who achieved molecular response and sustained it had better FFS than those who either reverted back to PCR-positive or who never achieved molecular response. Serial PCR analysis to determine the molecular response in FL correlates well with outcome especially when combined with pretreatment beta2-M.
Collapse
Affiliation(s)
- A López-Guillermo
- Department of Lymphoma, Laboratory Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91:1178-84. [PMID: 9454747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
To evaluate the incidence, risk factors, and outcome of central nervous system (CNS) recurrence in adult patients with non-Hodgkin's lymphoma, we evaluated 605 newly diagnosed patients with large-cell and immunoblastic lymphoma who participated in prospective chemotherapy studies. The Kaplan-Meier estimate of probability of CNS recurrence at 1 year after diagnosis was 4.5% (95% confidence interval [CI], 4.4 to 4.6). Twenty-four patients developed CNS recurrence after a median of 6 months from diagnosis (range, 0 to 44 months). In univariate analysis, an increased risk for CNS recurrence was associated with an advanced disease stage (P = .0014), an increased LDH (P = .0000), the presence of B-symptoms (P = . 0037), involvement of more than one extranodal site (P = .0000), poor performance status (P = .0005), and B-cell phenotype (P = .008). Bone marrow involvement (P = .005), involvement of parenchymal organs (P = .03), and involvement of skin, subcutaneous tissue, and muscle (P = .002) were also associated with an increased risk for CNS disease. Multivariate logistic regression analysis identified only involvement of more than one extranodal site (P = .0005) and an increased LDH (P = .0008) as independent predictors of CNS recurrence. Established CNS recurrence had a poor prognosis. Only 1 of 24 patients remains alive and the Kaplan-Meier estimate of probability of survival at 1 year after the diagnosis of CNS recurrence is only 25.3% (95% CI, 6.9 to 43.7). Intrathecal treatment provided symptomatic benefit in only 1 of 6 patients. Radiation treatment provided symptomatic improvement in 6 of 9 patients treated. However, remissions were short and followed by systemic or CNS recurrence. Serum LDH and involvement of more than one extranodal site are independent risk factors for CNS recurrence in patients with large-cell lymphoma. The presence of both risk factors identifies a patient group at high risk for CNS recurrence. Established CNS recurrence can be rapidly fatal. Transient responses occur after radiation treatment.
Collapse
Affiliation(s)
- K van Besien
- The Division of Medicine, Department of Hematology and Neuro-oncology, MD Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
Cutaneous T-cell lymphoma includes mycosis fungoides and the leukemic variant, Sézary syndrome. We report the first two cases of focal segmental glomerulosclerosis in patients with cutaneous T-cell lymphoma, with nephrotic range proteinuria and review the literature on renal disease coexisting with cutaneous T-cell lymphoma. We hypothesize that glomerular injury in cutaneous T-cell lymphoma may be related to interleukin-2.
Collapse
Affiliation(s)
- J C Cather
- Division of Medical Specialties, University of Texas Medical School, Houston, USA
| | | | | | | | | |
Collapse
|
43
|
Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 1997; 96:328-32. [PMID: 9029021 DOI: 10.1046/j.1365-2141.1997.d01-2012.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In order to determine the activity of paclitaxel in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), we conducted a phase II clinical trial in which eligible patients received paclitaxel 200 mg/m2 intravenously over 3 h. Treatment was repeated every 3 weeks. Patients achieving complete or partial responses after two courses of paclitaxel continued to receive therapy for a maximum of eight courses, otherwise they were removed from the study. Of 96 evaluable patients, 45 (47%) had primary refractory disease, and 51 (53%) had relapsed lymphoma. The median number of prior treatment regimens was two (range one to 10 regimens). 45 patients had lowgrade, 44 had intermediate-grade, and seven had mantle cell lymphoma. 24/96 patients responded (10 complete and 14 partial remissions) for an overall response rate of 25% (95% CI 17-35%). Patients with relapsed lymphoma had a higher response rate than those with primary refractory disease (19/51 = 37% v 5/45 = 11%; P < 0.01), and patients with relapsed intermediate-grade lymphoma had a higher response than those with relapsed low-grade lymphoma (9/18 = 50% v 10/31 = 32%; P = 0.22). The treatment was very well tolerated with the most common side-effects being alopecia (100%), peripheral neuropathy (35% of > or = grade II), and arthralgia/myalgia (25% of > or = grade II). After the first course of paclitaxel, grade III/IV thrombocytopenia and neutropenia were observed in 21% and 23% of the patients respectively. 23 episodes of neutropenic fever developed after 250 courses of paclitaxel therapy (8%). We conclude that paclitaxel, at this dose and schedule, is an active new drug for the treatment of non-Hodgkin's lymphoma. The activity of paclitaxel combination programmes are currently under investigation.
Collapse
Affiliation(s)
- A Younes
- Department of Hematology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Younes A, Ayoub JP, Sarris A, North L, Pate O, Mclaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Ann Oncol 1997; 8:129-131. [DOI: 10.1023/a:1008243009585] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol 1997; 8 Suppl 1:129-31. [PMID: 9187446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Paclitaxel (Taxol) was recently tested in patients with relapsed and refractory lymphoma in two phase II clinical trials using two different infusion schedules. The first, reported from the NCI (USA), used a 96-hour intravenous continuous infusion schedule, and the second, from our group, used a 3-hour infusion. In the NCI trial, 29 evaluable patients were treated with 140 mg/m2 every three weeks, which achieved a 17% response rate (all PRs); while we treated 96 evaluable patients with 200 mg/m/ every three weeks, which achieved a 25% response rate (10 CRs and 14 PRs, 95% CI: 17%-35%). In our trial, patients with relapsed (not primary refractory) intermediate-grade lymphoma had a response rate of 50%, and those with relapsed low-grade lymphoma had a response rate of 31%. In a follow-up trial, 12 patients who failed to respond to 3-hour infusion of paclitaxel were crossed over to receive paclitaxel by 96-hour infusion. None of the 12 evaluable patients achieved a major clinical response. Similarly, of 25 patients treated with cyclosporine A and paclitaxel after failing therapy with single-agent paclitaxel, only one patient (4%) responded. We conclude that paclitaxel has a promising single-agent activity, most prominently in patients with relapsed intermediate-grade lymphoma. Paclitaxel-based combination programs are currently being evaluated in our institution.
Collapse
Affiliation(s)
- A Younes
- Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Younes A, Ayoub J, Sarris A, North L, Pate O, McLaughlin P, Rodriguez M, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol®) for the treatment of lymphoma. Ann Oncol 1997. [DOI: 10.1093/annonc/8.suppl_1.s129] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Fayad L, Robertson LE, O'Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk Lymphoma 1996; 23:333-7. [PMID: 9031114 DOI: 10.3109/10428199609054836] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Patients developing Hodgkin's disease (HD) after a diagnosis of chronic lymphocytic leukemia (CLL), are frequently included in a series of patients with Richter's syndrome (RS). We sought to determine the natural history of the association of CLL and HD. Over a 21 year period, 1374 patients with CLL have been registered in our computer data base. Seven cases of CLL and HD have been documented and confirmed. The median age of these patients was 71 years (range 44-77) and clinical features included male gender (86%), B symptomatology (86%), rapidly progressive lymphadenopathy (71%), prior CLL therapy (71%), advanced Ann Arbor stage (86%), marrow involvement with HD (43%), and autoimmune hemolytic anemia (29%). HD was documented by excisional lymph node biopsy in six cases and splenectomy in one. Mixed cellularity HD was shown in six and nodular sclerosis in one. Five of the biopsies revealed intervening areas consistent with small lymphocytic lymphoma. The Sternberg-Reed (SR) cells were CD15+ in 6/7 cases, and Ki-1+ in the 6 patients tested. CD45 and CD20 staining of the SR cells was nonreactive. The median time to development of HD was 45 months (range 0 to 96). The overall responses to different chemotherapy regimens was approximately 25% with only one CR. Six patients have died at 3, 9, 10, 13, 15 and 36 months and one patient is alive with progressive disease at 11 months. Our data suggests that CLL patients have a heightened risk for HD, features of advanced HD on presentation, and a poor response rate with short survival.
Collapse
Affiliation(s)
- L Fayad
- Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:233-9. [PMID: 8558203 DOI: 10.1200/jco.1996.14.1.233] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE Cyclosporin A has been shown to reverse paclitaxel resistance in vitro by inhibiting P-gp function. Therefore, we determined whether addition of cyclosporine to paclitaxel reversed clinical paclitaxel resistance in patients with non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Patients with relapsed NHL were eligible if they had no intervening treatment after failure to respond to paclitaxel (200 mg/m2 over 3 hours), and if they had adequate marrow, renal, and hepatic function, no serious cardiac disease, no CNS involvement, and no antibodies to human immunodeficiency virus-1. A cyclosporin A bolus dose (5 mg/kg over 3 hours) was followed by intravenous infusion (15 mg/kg) over 24 hours. Six hours after the beginning of cyclosporin A, the immediately preceding paclitaxel dose was administered over 3 hours. All patients were premedicated with dexamethasone, diphenhydramine, and cimetidine. Response was assessed after two cycles, and those patients who achieved at least a partial response received a maximum of six courses. RESULTS All 26 patients entered were assessable for toxicity and 25 were assessable for response. One patient whose disease had progressed during paclitaxel treatment had a partial remission after the addition of cyclosporin A (response rate, 4%; 95% confidence interval, 1% to 20%). Disease progressed in 17 patients (71%) and did not respond in seven (25%). Serum cyclosporin A A levels measured at the time of initiation of paclitaxel infusion were greater than 2,000 ng/mL during 81% of cycles. Treatment toxicity included peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutropenic fever in 8%, and thrombocytopenia in 42% of patients. One patient with preexisting asthma had an acute bronchospasm during the first cycle and was removed from the study. There were no renal or hepatic toxicity and no infectious or hemorrhagic deaths. CONCLUSION Cyclosporin A administered on this schedule did not reverse established clinical resistance to paclitaxel, which suggests that P-gp-mediated drug efflux is unlikely to be the only cause of paclitaxel resistance in this patient population.
Collapse
Affiliation(s)
- A H Sarris
- Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17:427-33. [PMID: 7549833 DOI: 10.3109/10428199509056853] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support. Four patients were in untreated relapse, 7 had stable or progressive disease, 12 were in partial remission, and 11 were in complete remission after reinduction chemotherapy before proceeding to the preparative regimen. Median follow-up time is 22 months. Grades 3-4 regimen-related toxicity occurred in 3 (14%) of 22 patients treated with THIO 250 mg/m2 x 3, BU 1 mg/kg x 10 and CYC 50 mg/kg x 3, and this was considered the maximal tolerated dose-schedule. Of the 23 patients with active disease at the time of transplantation, 52% (95% CI 31-73%) achieved a complete response, and 26% (95% CI 10-48%) achieved a partial response. For all patients, median time to progression was 13 months, median survival was 16 months, and disease-free survival at 18 months was 34% (95% CI 18-51%). The combination of THIO, BU and CYC is tolerable as a preparative regimen for lymphoma and has a high response rate, but further measures are needed to reduce the relapse rate for patients with advanced disease.
Collapse
Affiliation(s)
- D Przepiorka
- Section of Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:583-7. [PMID: 7884419 DOI: 10.1200/jco.1995.13.3.583] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE Paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) is a novel antimicrotubule agent with anti-tumor activity against ovarian and breast carcinomas. Its activity when administered as a 3-hour intravenous infusion in patients with relapsed non-Hodgkin's lymphoma (NHL) has not been studied. PATIENTS AND METHODS Patients with relapsed NHL were treated with a 3-hour infusion of 200 mg/m2 of Taxol every 3 weeks in an outpatient setting. All patients received premedication (dexamethasone, diphenhydramine, and cimetidine) to prevent allergic reactions. Responses were assessed after two courses of therapy, and patients who achieved at least partial remission (PR) continued to receive Taxol for a maximum of eight courses. RESULTS Of 60 eligible patients, 54 (90%) were assessable for treatment toxicity and 53 (88%) were for treatment response (22 with primary refractory and 31 with relapsed disease). Twelve patients (23%) achieved a PR (n = 6) or complete remission (CR; n = 6) (95% confidence interval, 12% to 36%). Responses were observed in intermediate-grade (31%), low-grade (14%), and mantle-cell (17%) lymphomas. In the intermediate-grade lymphomas, there was a trend for a higher response rate in relapsed versus primary refractory disease (54% v 13%; P = .08). Treatment-related toxicity included alopecia (100%), peripheral neuropathy (37%), myalgia or arthralgia (25%), and neutropenic fever (11%). None of the patients had allergic reactions or cardiac toxicity. CONCLUSION At this dose and schedule, Taxol is an active agent in patients with relapsed NHL and can be safely administered in an outpatient setting. Combination programs with Taxol should be investigated for treatment of NHL.
Collapse
Affiliation(s)
- A Younes
- Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | | | | | | | | | | | |
Collapse
|